Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Miami, Lots of positive info surfacing as we get close to a significant PR
Surgitech has quite the client list JGD, Roche and many others
Surgitech was founded in 1998. Our business is the marketing and sale of diagnostic equipment and diagnostic and scientific reagents, as well as the maintenance of laboratory diagnostic instruments.
The company is growing bigger year by year and more diverse in terms of product range. At the end of 2017, we added new and exciting consumer products to our product portfolio. From now on, we also bring food supplements and other pharmacy products to the country.
Surgitech has been the sole representative of Roche Diagnostics GmbH in Estonia since 1999. Roche Diagnostics GmbH is one of the world's leading research and development diagnostics companies, part of the global healthcare group F. Hoffmann - La Roche Ltd.
https://www-roche-com.translate.goog/about/business/diagnostics.htm?_x_tr_sl=et&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=sc
https://www-surgitech-ee.translate.goog/ettevottest?_x_tr_sl=et&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
More Nonsense about BIEL's History & 2021 Achievements
<<<<<<<<< 2014 WAS crap. So was 2015. And 2016. And 2017. And 2018. And 2019. And 2020. And 2021 >>>>>>>>>
2015 was BIEL's highest Sales Year, $2.339 million
2016 was BIEL's 2nd highest @ $2.089 million.
2021 has reached $1.427 million at the 9 month mark.
More importantly BIEL has significantly reduced expenses when compared to its highest revenue years.
9 month values for 'Total General & Administrative' costs:
2015 - $2.487 million
2016 - $2.093 million
2021 - $871k
9 month values for 'Net Loss':
2015 - $2.114 million
2016 - $1.626 million
2021 - $162k
2021 is close to 2015 & 2016 in 9 month revenue, $1.42 vs $1.67, $1.68 million, and has slashed the 'Net Loss' by $1.9 million in comparison to 2015 & 1.4 million in comparison to 2016.
BIEL's OEM Business Plan is working and was a big part of BIEL's first profitable Quarter in Q3 2021.
It is called a Disclaimer to Limit Liability
ihub uses one also,
"Investors Hub does not endorse nor is it responsible for the content of the advertisements. We have not independently reviewed the information, claims and testimonials provided within the advertisement or the resulting landing pages and make no guarantee or warranty regarding such content. The opinions and recommendations expressed in the advertisement or the subsequent landing pages are not those of Investors Hub."
Looks like KT Expansion way ahead of Schedule Johny
Estonia, Latvia, Lithuania now selling KT Recovery + Wave
https://monger.eu/kttape/en/contact-us/
https://monger.eu/kttape/tooted/
https://monger.eu/kttape/en/
277504 - I just received another message from Russell Shawcroft Senior Director, International Sales of KT Tape's The Wave. I asked when will the wave be advertised nationally and internationally? Here's his response.
We have been advertising a bit here in the US, the international side will depend on country. We will start first in the UK and then branch out over time.
Still LMAO over yesterday's 'Pathetic' display of Fear over BIEL's growing Mojo
You don't expend that volume of ammunition in one day unless you are Desperate.
The dozens of derogatory posts did not work.
Buys = 12 million shares
Neutral = 4 million shares
Sells = 2 million shares
LOL, More 'Neural' transactions than 'Sells'.
Neutral is half way between the Bid and Ask SP which for BIEL requires a 5 digit to the right of the decimal point SP.
Retail investors can't place 5 digit orders, only MMs and Brokers can.
And some have been here all of those 18 years with the same schtick
<<<<<<<<<<< A 18 year old problem >>>>>>>>>>
"BIEL going into BK any day now"
"Andy told me RS in the works"
"SEC will shut down BIEL trading"
"BIEL drops again on Amazon Best Sellers"
"BIEL will never get FDA Cleared for anything"
"BIEL will never get FDA Reclassified"
"BIEL will never get FDA OTC Cleared"
"BIEL will never get CE Mark"
Veterans on the BIEL Board are very familiar with the scam
When one wants to Buy BIEL is 'snake oil' run by 'con artists'.
When one wants to Sell BIEL 'on fire' bound for new highs.
Excellent point bigkid
<<<<<< U MEAN LIKE A COMMERICAL ON TV????? >>>>>>>>>>>>
The poster , who feels BIEL is "Pathetic", must also have missed this disclosure at the end of the article,
"Disclosure: we hold no position in BIEL either long or short and we have not been compensated for this article"
Hmmmm, I recall somebody saying they were buying ay 9 a few weeks back
"I have a 25K order in at .0009"
"I will flip it at .0015 if we see trips."
You will get your wish soon toohot
BIEL hit 1.429 Billion Shares Traded on 2/6/2017 when the FDA Knee/Foot Clearence was granted.
Today we have FDA OTC Clearance for the Knee/Foot and every other Muscle, Joint, Tendon and Bone in the body!
Plus OEM Partners selling our devices in the US, Uk, and Australia!!
Our first profitable Quarter, Q3 2021, in BIEL's history!!!
Buckle Up as things get Fast & Furious very soon.
Thanks Hawk, Seems like we have to have new ROW Distribution with the number of new retailers that keep popping up outside the US
I am still holding out hope for billion $$$ STADA as a distribution Partner.
https://www.stada.com/about-stada/who-we-are
On another topic, some were wondering why there was so much selling today.
Have to refer those inquiries to the Marker Makers who Failed to Deliver 59 million shares today.
20220103|BIEL|59263710|0|76135596
https://cdn.finra.org/equity/regsho/daily/FORFshvol20220103.txt
Adison is an Indian based Medical Supply company with connections to Covidien & Abbott.
"We have strong relations with all the key customers in India. We have a good acceptance by all the Senior Physicians & administration Executives of various Hospitals in the country. We will be working directly in all the Hospitals in Delhi & the rest of the places through our partners."
"Rich Experience of Launching & establishing new products in the Market Place."
http://www.adison.in/
Forgo - omit or decline to take (something pleasant or valuable); go without.
The word 'forgo' was used in the 'Update'.
Defer - Put off (an action or event) to a later time; postpone.
The word 'defer' would have been used if the interest would be due at a later date.
Both IBEX and St John's have been 'deferring' interest payments for years as BIEL did not have the resources to make interest payments.
The last sentence in the paragraph further clarifies that the lenders "forfeited interest".
"The Whelan family has collectively forfeited interest in excess of $1.5 million during 2020 and 2021 and will extend forbearance of interest through at least 2022.”
I think the Update was just miss dated as 2021 rather than 2022
I do not show any 01/03/2021 emails from BIEL. The first one I show for 2021 was on 01/19/2021 about Q4 revenue increase.
All of the information in the Update released today is from 2021 events not 2020 events.
Hopefully E&E corrects this error before the PR is published on Monday.
Need to reread my 12/29 post, the PR that will bring in new money comes in January
srinsocal Wednesday, 12/29/21 06:07:20 PM
Re: Miamifl post# 281715 0
Post # 281725 of 281939
Thanks Miami, IMO important to understand that the 'EOY Update' will most likely be geared toward informing existing investors not bringing in new investors.
A PR aimed at attracting investors on the holiday week between Christmas & New Year's would go unnoticed by too many.
I am looking for a PR properly promoting BIEL's achievements in January when the holiday distractions are gone. This could be an extremely consequential PR for both BIEL & BIEL shareholders.
Yup as Promised, EOY Update
Release #:812-220316-rl-1190694:
BIOELECTRONICS CORPORATION ANNOUNCES MAJOR LENDERS FORGOING INTEREST FOR A 3rd CONSECUTIVE YEAR; NEW RESEARCH PROJECTS UNDERWAY (This will be issued Monday a.m.)
FREDERICK, MARYLAND, January 3, 2021 - BioElectronics Corporation (OTC PINK:BIEL) is pleased to announce that the managers of the firm’s two largest lenders, Ibex LLC and St. John’s LLC, both of which are controlled by Whelan family members, have agreed to forgo interest due on their convertible debt notes for a third consecutive year, through the end of 2022. Kelly Whelan, President & CEO of BioElectronics, stated: “It is the goal of both the BioElectronics’ management team and the Whelan family to bring the Company to sustained profitability as quickly as possible, for the benefit of all shareholders. The Whelan family has collectively forfeited interest in excess of $1.5 million during 2020 and 2021 and will extend forbearance of interest through at least 2022.”
In other news, the Company has continued its engagements in basic and applied research. Three projects of note were started over the last six months. The first, which is viewed by the Company as basic research, was launched in the Summer of 2021 and aimed at achieving a new intended use (and in all likelihood develop a new medical device) based on our core capabilities in pulsed short-wave therapy (PSWT). The goal is to investigate whether PSWT can serve as a therapeutic intervention for psychological disorders such as depression and anxiety, through brain stimulation. Preliminary physiologic data indicated that it is possible to identify brain waves associated with anxiety, using cutting edge brainwave assessment technology (wireless electroencephalography). The Company is expanding the "brain stimulation project" by collaborating with Dr. Ken McLeod at Binghamton, with the aim of investigating whether PSWT can influence brain wave activity associated with anxiety. Dr. McLeod is a clinical/engineering research consultant to the Company and a world-renowned expert on bioelectromagnetics research.
The second research project involves determining the effectiveness of our 720 hours medical device to relieve pain and increase functionality in dogs suffering from arthritis. In the Fall of 2021, the Company partnered with a veterinary physiotherapy researcher located in the UK to conduct a study on 70 dogs that have been diagnosed with severe arthritis. In working out the details of the study, our research team of Dr. Sree Koneru, Dr. Ken McLeod and our Chairman, Dr. Richard Staelin, not only made numerous suggestions on how to improve the study protocol, but also came up with a new design modification for our current device – the intent is to increase the likelihood of providing significant pain relief for the treated dogs. The Company has finalized this new design and is working with our manufacturer to produce the needed 70 devices. With a slated start date in mid-January of 2022, the study is expected to be completed by late Spring of 2022.
The third project also involves an undertaking to determine the effectiveness of the device for a new intended use, i.e., pain reduction and/or improvement in healing rates of chronic wounds. The Company’s management is currently in discussions with a wound research group to conduct a study on whether the RecoveryRx medical device can provide pain relief to those who suffer with chronic lower limb venous ulcers. A venous leg ulcer is the most common type of leg ulcer, accounting for more than 90% of all cases. Venous leg ulcers can develop after a minor injury, where persistently high pressure in the veins of the legs has damaged the skin. While the name of this group cannot yet be disclosed, their team is recognized internationally for being at the forefront of wound healing research. Their large patient volume affords them the ability to conduct clinical trials quickly and efficiently, with more than 100 clinical trials conducted on growth factors, gene therapy, bioengineered skin products and novel pharmaceuticals. Their research efforts have produced more than 130 abstracts, 100 manuscripts and 900 presentations worldwide.
Finally, BioElectronics is actively seeking partners towards our goal of expanding our technology’s indications for use. Specifically, the goal is to put together a basic and applied research plan for various clinical disorders that are closely linked to the etiology behind many types of chronic pain, i.e. central sensitization. Some of these disorders include, but are not limited to, overactive bladder (about 33 million Americans have overactive bladder), vulvodynia (as many as 16 percent of women in the U.S. suffer from vulvodynia at some point in their lives), and other treatment-resistant conditions. These approaches are in line with our overall goal of continuing to invest in research and development.
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements
LOL, like it takes an office full of people to hit 'send' and have an 'Update' email distributed to Shareholders or a PR scheduled for release which would be handled by E&E in either case.
<<<<<<< BIEL closed their office yesterday for the holiday so it's unlikely they'll "have something out before year end." >>>>>>>>
More premature complaining to create selling.
Another BIEL Classic, Complaining about missing a deadline 28 hours before the deadline
<<<<<< It’s another excuse, nothing more. Tomorrow is the last day for the update >>>>>>
Save the contempt for midnight on 12/31/2021. If there is no 'BIEL Update' produced by then I will also express dissatisfaction.
If there is an 'Update' by midnight KW will have met her commitment and I am sure those who questioned her doing so will acknowledge that fact.
Classic Move, bring up a half truth from 2018 and 12 minutes later complain that one of the most important events in BIEL's History from 2020 is "Old news"
BIEL's 2020 FDA Full Body Musculoseletal Pain Clearance was the result of 18 years of hard work in getting the FDA to accept PEMF/PSWT, technology they did not understand, as a safe and effective Pain Relief Device useable on all muscles, bones, and joints in the body. It will never be "Old news".
This Full Body Clearance is what got the KT Tape and Scott/DonJoy OEM Deals signed.
The 2018 Opioid Challenge was the FDA's Plan to stimulate new technology that would reduce the damage that Opioid abuse has caused. It involved the following Categories:
Opioid Use Disorder Therapy
Medication Dispensing
Monitoring
Overdose Therapy
Pain Therapy
Medication Dispensing
Other
There was no Pass/Fail grade handed out for the 2018 Opioid Challenge.
250 companies submitted proposals for their products or their product development projects.
A total of 8 proposals were accepted into the Challenge.
Several of the 242 companies that were not selected had $100 million + R&D Budgets.
Another one of many BS posts headed to the Circular File
<<<<<<< COVID actually made the share price INCREASE >>>>>>>>
<<<<<<< Bankruptcy is being whispered throughout the company >>>>>>>>
<<<<<<< I only state facts. Prove me wrong >>>>>>>
<<<< This (BIEL) is no different than a person who sits at home and does drop shipping >>>>
<<<<<<<< The stock has made me about $50K to date >>>>>>>>
<<<<<<< I’m definitely not a MM or associated with any >>>>>>>>
<<<<<<< BIEL definitely isn’t being naked shorted >>>>>>>>
<<<<<<<<<<<< This company is dead >>>>>>>>>>>>
Thanks Miami, IMO important to understand that the 'EOY Update' will most likely be geared toward informing existing investors not bringing in new investors.
A PR aimed at attracting investors on the holiday week between Christmas & New Year's would go unnoticed by too many.
I am looking for a PR properly promoting BIEL's achievements in January when the holiday distractions are gone. This could be an extremely consequential PR for both BIEL & BIEL shareholders.
Sub-Penny stocks are very easy to manipulate,,,,,
Until significant news is released publicly.
Volume rises and manipulation becomes more risky.
BIEL is a News Driven Stock. BIEL has been unusually quiet since March of 2021 hence the SP drop.
What happens when BIEL releases significant news:
01/19/2021 - 372 million Volume
01/26/2021 - 426 million Volume
01/27/2021 - 297 million Volume
02/11/2021 - 465 million Volume
02/12/2021 - 426 million Volume
02/25/2021 - 470 million Volume
01/08/2020 - 316 million Volume
02/28/2020 - 426 million Volume
12/15/2020 - 237 million Volume
07/01/2019 - 753 million Volume
08/02/2019 - 536 million Volume
04/20/2018 - 317 million Volume
04/27/2018 - 266 million Volume
05/01/2018 - 390 million Volume
05/02/2018 - 949 million Volume
11/27/2018 - 798 million volume
02/03/2017 - 381 million Volume
02/06/2017 - 1.429 billion Volume
02/07/2017 - 667 million Volume
02/09/2017 - 357 million Volume
02/10/2017 - 226 million Volume
02/13/2017 - 306 million Volume
02/14/2017 - 569 million Volume
02/15/2017 - 278 million Volume
02/21/2017 - 520 million Volume
02/22/2017 - 519 million Volume
02/27/2017 - 243 million Volume
02/28/2017 - 595 million volume
03/01/2017 - 325 million Volume
03/02/2017 - 343 million Volume
Hmmmm, I am hearing a different 'Whisper throughout the company'
Increase in Sales Revenue
New Partners
KT expanding into New Countries with The Wave
SAI Launching their 10 'ActiPatch Enhanced' Products in Q1 2022
The Update is Real and coming this Year!
JG, Looks like 'Update' origin goes back to an Erinmoon post #281269
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167223031
With The_Pro providing a FB screen shot in post #281271 .
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167223373
Thanks to both for providing this valuable info to the Board.
Give Me a Break, there will be an Update by 12/31/2021
<<<<<< so will she keep her promise, it remains to be seen >>>>>>>
KW Quote:"We Will Have an Update Soon! Planning to Have Something Out Before Years End"
The CEO of a company does not tease about something as simple to do as an 'Update' by a specific date without delivering.
It may not contain every detail some are looking for, and I am sure they won't be shy about complaining, but there will be an 'Update' this year!*
* Is my exclamation point an expression of excitement, a strong declaration, or anger? LMAO
The Wave is still doing better than 3,838 other products in the category
And that is with only being on the Market 10 months. Some competitors have been around for 17 years building brand recognition.
Date First Available : November 22, 2004
Manufacturer : Tiger Balm
Date First Available : June 23, 2006
Manufacturer : Prestige Consumer Healthcare
Date First Available : December 13, 2012
Manufacturer : Prestige Consumer Healthcare
Thanks Miami, Ibuprofen is a Real Gem, only 34 Side Effects:
constipation
diarrhea
gas or bloating
dizziness
nervousness
ringing in the ears
unexplained weight gain
shortness of breath or difficulty breathing
swelling of the abdomen, feet, ankles, or lower legs
fever
blisters
rash
itching
hives
swelling of the eyes, face, throat, arms, or hands
difficulty breathing or swallowing
hoarseness
excessive tiredness
pain in the upper right part of the stomach
nausea
loss of appetite
yellowing of the skin or eyes
flu-like symptoms
pale skin
fast heartbeat
cloudy, discolored, or bloody urine
back pain
difficult or painful urination
blurred vision, changes in color vision, or other vision problems
red or painful eyes
stiff neck
headache
confusion
aggression
Classic, complaining about 'BIEL'S horrible math' in a post that contains a $594,000 math error.
LOL, Nothing is ever "Very Good" when some give their Opinion
Nor is it "Fast Enough".
Should have been a "de novo rather than a 510k".
Should have used "Bank Loans rather than dilution".
Should have won the "Opioid Challenge".
Et cetera, et cetera, et cetera.
Merry Christmas to All BIEL Longs & a Prosperous New Year!!!
Thanks rdw, Another Clue for those paying attention
"Seeking Researchers" for a new RecoveryRx Indication.
This takes money for the Research, money for the Clinical Studies, money to develop a new 510k Application.
Sounds like BIEL may be able to fund a larger R&D budget in the very near future. Only $73k spent on R&D last Quarter.
Very possible new Rx Partner wants to expand the uses of RecoveryRx.
https://twitter.com/hashtag/vulvodynia?src=hashtag_click
No Amazon update in 40 hours can only mean 1 thing .....
Sure enough, The Wave advanced to #91 out of over 4,000 products in its category!!
"#91 in Pain Relief Homeopathic Remedies"
Go BIEL !!!
Go KT Wave !!!
Surgical Appliance Industries has a Canadian operation, Airway Specialties
They are both listed on the FDA Establishment Registration Database,
Yep Pro, Two of Many Clues that Point to Better Access to Drug Free Pain Relief for Patients and a Prosperous New Year for BIEL Longs!
Go BIEL !!!
Go RecoveryRx !!!
Go KT Tape US !!!
Go KT Tape UK !!!
Go KT Tape AU !!!
Go KT Tape Japan !!!
Go DJO !!!
Go SAI !!!
Go ASA !!!
Multiple opinions from sources, who have been correct in the past, feel that there has been a significant Rx deal brewing for months and it will soon be ready for public consumption.
Those opinions are available if one does some digging and can do basic math.
Do your own DD before making investment decisions with your hard earned money.
For those with a short memory:
* ActiPatch was on the UK shelves of Lloyds, Boots, Super Drug, Weldricks
* BIEL had its highest Sales Revenue during the UK years
* BIEL also had its highest 'Net Losses' during the UK years
* The costs of maintaining a Retail presence in thousands of stores was greater than the gross profits
* When ActiPatch got NHS Coverage in 2018 BIEL pulled out of the Retail stores
* The Local NHS CCG bureaucracy has been slow to adopt ActiPatch use
* No longer on Retail shelves and not available through NHS due to CCG restrictions
* UK customers went from having ActiPatch in thousands of stores to trying to track it down online
* This was a Supply & Regulation Issue not a Demand issue
The good news is that this experience was important in making BIEL realize that trying to go it alone with a retail sales strategy was not viable.
Two years later in 2020 BIEL started the transition to a OEM Business Model.
Q3 2021 saw BIEL's first Profitable Quarter due to the change to a OEM strategy.
BIEL sells Devices to a prominent Brand, KT Tape. KT Tape, with their established Retail Network, handles all costs associated with Retail Distribution & Marketing.
Ridiculous argument, ActiPatch has been OTC in the UK for years
In the UK the only reason for an ActiPatch prescription is to have the cost covered by the National Health Service.
If the Patient is paying they can buy it OTC or online with no prescription. That is what 'Gary' had to do because his Community NHS would not pay for it.
https://www.mirror.co.uk/news/uk-news/ive-cured-chronic-back-pain-14985643
<<<<<<<<< Already preparing excuses for the terrible Q4 we all know is coming? >>>>>>>>>>>>
Wrong again. Preparing for the arrival of a new BIEL Partner 'we all know is coming'.
In the UK it is not a matter of doctors refusing to prescribe ActiPatch
It is a matter of doctors can't prescribe due to the Community NHS Groups not authorizing its use even though the National NHS has Approved Coverage.
In the US it is a matter of 99% of doctors are unaware of the non-drug pain relievers ActiPatch/RecoveryRx. This lack of knowledge starts to change in January.
Apparently I was not clear enough, I will let Gary tell the story
'I've cured my chronic back pain with £19 patch - but NHS won't prescribe it'
Gary Meek, from Harlow in Essex, claims he has saved the NHS £8,000 in less than three years and wants the patch available to other sufferers
The Mirror
ByJane LavenderAssociate Editor
09:28, 3 May 2019
A retired teacher claims a £19 patch has cured his chronic back pain and freed him from a life of prescription painkillers - but says the NHS still won't prescribe it to him.
says a revolutionary drug-free treatment rescued him from a cocktail of opioid painkillers and saved the NHS £8,000 in barely two-and-a-half years—but doctors STILL won't prescribe it to him.
Gary Meek, 62, from Harlow, Essex, suffers from degenerative disc disorder – a debilitating condition which causes chronic lower back pain.
He says the ActiPatch has saved the NHS £8,000 a year and is calling for it to be available to other sufferers.
Gary's agonising back pain forced him into early retirement at just 55 from his work as Senior Lecturer in Post Graduate Certificate of Education training IT Teachers at Middlesex University.
And years of coping through intense NHS-prescribed opioids and painkillers like duloxetine and fentanyl left the father-of-two wondering whether the pain or the side effects of medication were worse.
But that all changed when a fellow patient introduced him to a device that uses electromagnetic pulses to treat pain while on a pain management programme at St Thomas’ Hospital, in London.
He has now been using Actipatch for around 30 months and says it has been vital to him being able to reduce intake of a cocktail of painkilling drugs—including fentanyl.
Actipatch is a drug-free relief system, which helps manage joint and muscle pain using 1,000 electromagnetic signal pulses a second.
Gary says he has struggled to get the treatment prescribed on the health service, despite claiming he has cut more than £8,000-worth of drug intake over 30 months.
According to NHS data, doctors prescribed the equivalent of 79 opioid pill packs per minute in 2017, and the number prescribed by GPs has risen by 10 million in a decade.
Last month, the Royal College of General Practitioners announced that GPs did not want to prescribe them for long-term use.
RCGP chair Helen Stokes-Lampard said most patients don’t want to take medication long-term and it was “frustrating for all involved that there is a lack of alternative treatments available”.
But Gary claims he has tried and failed to get the drug free alternative on the NHS despite it being available for prescription since April 2018.
He added: “I can’t see why the NHS isn’t looking at something like Actipatch as a genuine drug-free option for people suffering with chronic pain.
“Unfortunately, the good it is doing is being ignored. The financial side of it especially is just amazing.
“While on the pain-killing drugs, I saw the prescribing books and know how much each of them cost.
"And you only have to do some simple arithmetic to multiply the cost savings by the length of time a patient might be taking the drugs.
“For people suffering long-term pain, the costs and dangers are potentially huge.
“The NHS has said it wants people off opioids, and you’ve only got to multiply that by 100, 1,000 or however many could be benefitting.”
After initially buying it for himself, Gary then mentioned it to his GP.
He said: "She’d never heard of it. I explained how it worked for me but she was unable to prescribe it for me as the request to the CCG was refused on the basis of there being ‘no evidence’ to support the benefits.
“But that is not the case everywhere. Through my research, there are some CCGs who are prescribing Actipatch, but there’s currently only about 20.
Actipatch has been sanctioned for prescription since April 2018, and is included on the NHS Drug Tariff Pages.
But according to Gary’s research, only a handful of CCGs recommend or prescribe the treatment, including two in Lincolnshire and Hampshire.
Read the full story here, https://www.mirror.co.uk/news/uk-news/ive-cured-chronic-back-pain-14985643
100% Wrong, After months of review the national UK NHS added ActiPatch to their 'Drug Tariff' meaning any NHS doctor could prescribe it.
<<<<<<< That was their reason for not approving/prescribing the ActiPatch >>>>>>>>
So ActiPatch is Approved for use and coverage in the UK at the national NHS level.
The NHS has been strapped for cash for the past decade. This results in the local NHS managers, called CCGs, having to care for patients with less money each year.
The CCGs made the decision to exclude ActiPatch from the Local list of Approved drugs and medical devices, as they have done with many other new products, that their local doctors could prescribed as a cost cutting measure. They used the 'more studies needed' excuse just as the US Health Insurers have done.
BIEL made the decision to pull ActiPatch from UK shelves in 2018 due to the NHS Coverage Approval and the high cost of 'Slotting and Distributor Fees' when you are on thousands of shelves.
<<<<<<<<<<< sales decreased and dwindled to insignificance >>>>>>>>>>>
Here are the costs BIEL had during the 2 highest years of UK Sales compared to the first 9 months of 2021:
......................... 2015 .................. 2016 .............. 2021(9 mo)
Sales .......... $2.339 million ...... $2.089 million ...... $1.427 million
Costs(TGA).. $3.128 million ..... $2.658 million ......... $871k
Net Loss ...... $2.450 million ..,,,. $2.106 million ........ $162k
It is clear that the costs of BIEL handling their own distribution/marketing were not a viable path to profitability.
As the 2021 Financials show the OEM strategy drastically cuts costs and does provide a path to profitability.